DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight, 2023,” report provides comprehensive insights about 125+ companies and 130+ pipeline drugs in Soft Tissue Sarcoma pipeline landscape. It covers the Soft Tissue Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Soft Tissue Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Soft Tissue Sarcoma Pipeline Report
- DelveInsight’s Soft Tissue Sarcoma pipeline report depicts a robust space with 125+ active players working to develop 130+ pipeline therapies for Soft Tissue Sarcoma treatment.
- The leading companies working in the Soft Tissue Sarcoma Market include Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
- Promising Soft Tissue Sarcoma Pipeline Therapies in the various stages of development include Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, Doxorubicin, and others.
- December 2023: Epizyme Inc. announced a study of Phase 3 clinical trials for Tazemetostat and Doxorubicin HCl. The open-label phase 1b portion is designed to evaluate the safety of the combination of tazemetostat + doxorubicin, as well as to establish the maximum tolerated dose (MTD) and the RP3D. The phase 3 portion of the clinical trial aims to compare tazemetostat + doxorubicin to the current front-line standard treatment, single-agent doxorubicin + placebo, when used as first-line treatment in locally advanced unresectable or metastatic ES.
- November 2023: Lytix Biopharma AS announced a study of Phase 2 clinical trials for LTX-315 and TILs. An Open Label Phase II Single Centre Study Investigating the Safety and Efficacy of LTX-315 and Adoptive T-cell Therapy in Patients With Advanced/Metastatic Soft Tissue Sarcoma (ATLAS-IT-04).
Request a sample and discover the recent advances in Soft Tissue Sarcoma Treatment Drugs @ Soft Tissue Sarcoma Pipeline Outlook Report
In the Soft Tissue Sarcoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Soft Tissue Sarcoma Overview
Soft tissue sarcoma is a disease in which malignant (cancer) cells form in the soft tissues of the body. Having certain inherited disorders can increase the risk of soft tissue sarcoma. A sign of soft tissue sarcoma is a lump or swelling in soft tissue of the body. Soft tissue sarcoma is diagnosed with a biopsy.
Find out more about Soft Tissue Sarcoma Treatment Landscape @ Drugs for Soft Tissue Sarcoma Treatment
Soft Tissue Sarcoma Emerging Drugs Profile
- AL3818: Advenchen Laboratories
- L19 TNF: Philogen
- Camsirubicin: Monopar Therapeutics
Soft Tissue Sarcoma Pipeline Therapeutics Assessment
There are approx. 125+ key companies which are developing the therapies for Soft Tissue Sarcoma. The Soft Tissue Sarcoma companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Advenchen Laboratories, LLC.
DelveInsight’s Soft Tissue Sarcoma pipeline report covers around 130+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
Soft Tissue Sarcoma Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Learn more about the emerging Soft Tissue Sarcoma Pipeline Therapies @ Soft Tissue Sarcoma Clinical Trials Assessment
Scope of the Soft Tissue Sarcoma Pipeline Report
- Coverage- Global
- Soft Tissue Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Soft Tissue Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Soft Tissue Sarcoma Companies- Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
- Soft Tissue Sarcoma Pipeline Therapies- Olaratumab, Pembrolizumab, NBTXR3, Glufosfamide, PXD101, Doxorubicin, and others.
Dive deep into rich insights for new drugs for Soft Tissue Sarcoma treatment, Visit @ Soft Tissue Sarcoma Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Soft Tissue Sarcoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Soft Tissue Sarcoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Anlotinib: Advenchen Laboratories, LLC
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Camsirubicin: Monopar Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- FHD-609: Foghorn Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Soft Tissue Sarcoma Key Companies
- Soft Tissue Sarcoma Key Products
- Soft Tissue Sarcoma- Unmet Needs
- Soft Tissue Sarcoma- Market Drivers and Barriers
- Soft Tissue Sarcoma- Future Perspectives and Conclusion
- Soft Tissue Sarcoma Analyst Views
- Soft Tissue Sarcoma Key Companies
- Appendix
For further information on the Soft Tissue Sarcoma Pipeline Therapeutics, reach out @ Soft Tissue Sarcoma Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market